S&P 500   5,062.56 (+1.62%)
DOW   38,883.30 (+0.70%)
QQQ   435.61 (+2.35%)
AAPL   182.97 (+0.36%)
MSFT   411.27 (+2.26%)
META   485.56 (+3.75%)
GOOGL   144.23 (+1.18%)
AMZN   172.54 (+2.34%)
TSLA   193.06 (-0.88%)
NVDA   777.30 (+15.20%)
NIO   5.74 (-3.85%)
AMD   180.03 (+9.58%)
BABA   75.54 (-0.05%)
T   16.62 (-2.24%)
F   12.21 (+0.58%)
MU   85.42 (+4.82%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.01 (+0.32%)
AMC   4.54 (-0.66%)
PFE   27.23 (-1.59%)
PYPL   57.59 (+0.19%)
XOM   104.44 (-0.39%)
S&P 500   5,062.56 (+1.62%)
DOW   38,883.30 (+0.70%)
QQQ   435.61 (+2.35%)
AAPL   182.97 (+0.36%)
MSFT   411.27 (+2.26%)
META   485.56 (+3.75%)
GOOGL   144.23 (+1.18%)
AMZN   172.54 (+2.34%)
TSLA   193.06 (-0.88%)
NVDA   777.30 (+15.20%)
NIO   5.74 (-3.85%)
AMD   180.03 (+9.58%)
BABA   75.54 (-0.05%)
T   16.62 (-2.24%)
F   12.21 (+0.58%)
MU   85.42 (+4.82%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.01 (+0.32%)
AMC   4.54 (-0.66%)
PFE   27.23 (-1.59%)
PYPL   57.59 (+0.19%)
XOM   104.44 (-0.39%)
S&P 500   5,062.56 (+1.62%)
DOW   38,883.30 (+0.70%)
QQQ   435.61 (+2.35%)
AAPL   182.97 (+0.36%)
MSFT   411.27 (+2.26%)
META   485.56 (+3.75%)
GOOGL   144.23 (+1.18%)
AMZN   172.54 (+2.34%)
TSLA   193.06 (-0.88%)
NVDA   777.30 (+15.20%)
NIO   5.74 (-3.85%)
AMD   180.03 (+9.58%)
BABA   75.54 (-0.05%)
T   16.62 (-2.24%)
F   12.21 (+0.58%)
MU   85.42 (+4.82%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.01 (+0.32%)
AMC   4.54 (-0.66%)
PFE   27.23 (-1.59%)
PYPL   57.59 (+0.19%)
XOM   104.44 (-0.39%)
S&P 500   5,062.56 (+1.62%)
DOW   38,883.30 (+0.70%)
QQQ   435.61 (+2.35%)
AAPL   182.97 (+0.36%)
MSFT   411.27 (+2.26%)
META   485.56 (+3.75%)
GOOGL   144.23 (+1.18%)
AMZN   172.54 (+2.34%)
TSLA   193.06 (-0.88%)
NVDA   777.30 (+15.20%)
NIO   5.74 (-3.85%)
AMD   180.03 (+9.58%)
BABA   75.54 (-0.05%)
T   16.62 (-2.24%)
F   12.21 (+0.58%)
MU   85.42 (+4.82%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.01 (+0.32%)
AMC   4.54 (-0.66%)
PFE   27.23 (-1.59%)
PYPL   57.59 (+0.19%)
XOM   104.44 (-0.39%)

Twist Bioscience (TWST) Competitors

$38.25
-0.11 (-0.29%)
(As of 10:27 AM ET)

TWST vs. RXRX, VCEL, KYMR, IOVA, DNLI, BEAM, APGE, INBX, AMAM, and NMRA

Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Recursion Pharmaceuticals (RXRX), Vericel (VCEL), Kymera Therapeutics (KYMR), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Apogee Therapeutics (APGE), Inhibrx (INBX), Ambrx Biopharma (AMAM), and Neumora Therapeutics (NMRA). These companies are all part of the "biological products, except diagnostic" industry.

Twist Bioscience vs.

Recursion Pharmaceuticals (NASDAQ:RXRX) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.

Recursion Pharmaceuticals currently has a consensus price target of $12.00, suggesting a potential downside of 2.99%. Twist Bioscience has a consensus price target of $37.40, suggesting a potential downside of 2.50%. Given Recursion Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Twist Bioscience is more favorable than Recursion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25
Twist Bioscience
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Twist Bioscience has higher revenue and earnings than Recursion Pharmaceuticals. Twist Bioscience is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$39.84M67.26-$239.48M-$1.46-8.47
Twist Bioscience$245.11M9.05-$204.62M-$3.61-10.63

In the previous week, Recursion Pharmaceuticals had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 21 mentions for Recursion Pharmaceuticals and 6 mentions for Twist Bioscience. Recursion Pharmaceuticals' average media sentiment score of 1.00 beat Twist Bioscience's score of 0.22 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
9 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Twist Bioscience
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Twist Bioscience has a net margin of -78.44% compared to Twist Bioscience's net margin of -617.74%. Recursion Pharmaceuticals' return on equity of -32.16% beat Twist Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-617.74% -64.20% -44.56%
Twist Bioscience -78.44%-32.16%-26.09%

Twist Bioscience received 67 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 55.26% of users gave Twist Bioscience an outperform vote while only 45.95% of users gave Recursion Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Recursion PharmaceuticalsOutperform Votes
17
45.95%
Underperform Votes
20
54.05%
Twist BioscienceOutperform Votes
84
55.26%
Underperform Votes
68
44.74%

Recursion Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.

57.8% of Recursion Pharmaceuticals shares are owned by institutional investors. 20.0% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 3.9% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Twist Bioscience beats Recursion Pharmaceuticals on 12 of the 18 factors compared between the two stocks.


Get Twist Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TWST vs. The Competition

MetricTwist BioscienceBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$2.22B$2.68B$4.96B$7.32B
Dividend YieldN/A2.40%2.91%3.85%
P/E Ratio-10.637.96133.0118.19
Price / Sales9.05327.653,179.55159.06
Price / CashN/A22.1689.8154.06
Price / Book3.763.844.284.56
Net Income-$204.62M$60.70M$112.46M$207.35M
7 Day Performance-7.57%-0.35%0.67%-0.95%
1 Month Performance10.36%9.15%5.93%3.18%
1 Year Performance84.16%4.37%7.39%3.35%

Twist Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXRX
Recursion Pharmaceuticals
0.2355 of 5 stars
$9.80
-10.4%
$12.00
+22.5%
+60.4%$2.12B$39.84M-6.71550Upcoming Earnings
Insider Selling
Gap Up
VCEL
Vericel
1.0489 of 5 stars
$45.95
-3.1%
$44.40
-3.4%
+68.2%$2.19B$163.70M-199.78305Upcoming Earnings
KYMR
Kymera Therapeutics
0.2092 of 5 stars
$35.03
-3.8%
$35.88
+2.4%
+25.9%$1.94B$46.83M-12.21192Insider Selling
News Coverage
Gap Up
IOVA
Iovance Biotherapeutics
4.8616 of 5 stars
$9.16
-7.9%
$20.91
+128.3%
+124.3%$2.34BN/A-4.43503Upcoming Earnings
Analyst Report
Insider Buying
Options Volume
Analyst Revision
News Coverage
Positive News
Gap Down
DNLI
Denali Therapeutics
3.9706 of 5 stars
$17.06
-8.0%
$48.20
+182.5%
-42.5%$2.37B$108.46M-17.59447Upcoming Earnings
Analyst Report
BEAM
Beam Therapeutics
1.7194 of 5 stars
$29.98
-10.2%
$43.92
+46.5%
-19.3%$2.44B$60.92M-7.19439Upcoming Earnings
APGE
Apogee Therapeutics
0.5046 of 5 stars
$35.80
+0.8%
$38.33
+7.1%
N/A$1.81BN/A0.0025Upcoming Earnings
INBX
Inhibrx
3.7858 of 5 stars
$37.25
-1.6%
$36.50
-2.0%
+66.2%$1.76B$2.19M-8.76132Positive News
AMAM
Ambrx Biopharma
0.2603 of 5 stars
$27.77
-0.1%
$24.13
-13.1%
+508.8%$1.75B$7.40M0.0087Positive News
NMRA
Neumora Therapeutics
0.1449 of 5 stars
$17.72
-1.9%
$21.29
+20.1%
N/A$2.71BN/A0.0094Gap Down

Related Companies and Tools

This page (NASDAQ:TWST) was last updated on 2/22/2024 by MarketBeat.com Staff